AIP
PFE icon

Arrowpoint Investment Partners’s Pfizer PFE Stock Holding History

Arrowpoint Investment Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80,000
Closed -$2.04M – 137
2025
Q3 		$2.04M Buy
+80,000
New +$1.97M 2.04% 12

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Arrowpoint Investment Partners's PFE Position: Q1 2026 in Review

Arrowpoint Investment Partners increased its Pfizer (PFE) stake by 65% in Q1 2026, buying an estimated $745K and bringing the position to 71,313 shares worth $2M. The position accounts for 1.78% of the portfolio, ranked #13.

Arrowpoint Investment Partners first reported a position in PFE in Q4 2025 and has held it in 2 quarters since. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Arrowpoint Investment Partners held 71,313 shares of Pfizer worth $2M as of Q1 2026.
  • Arrowpoint Investment Partners bought 27,971 Pfizer shares in Q1 2026, an estimated $745K.
  • Pfizer made up 1.78% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #13 holding.
  • Arrowpoint Investment Partners first reported a position in Pfizer in Q4 2025 and has held it in 2 quarters since.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.